Evidence map›Paper›PMID 34953602›Full record

ArticleEuropean urology2022

Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy.

Matthew Mossanen, Filipe L F Carvalho, Vinayak Muralidhar, Mark A Preston, Brendan Reardon, Jake R Conway, Catherine Curran, Dory Freeman, Sybil Sha, Guru Sonpavde and 4 more

Open access · greenAbstract read
In one paragraph

Article in European urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Matthew MossanenDivision of Urologic Surgery, Brigham & Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA, USA.
Filipe L F CarvalhoDivision of Urologic Surgery, Brigham & Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA, USA.
Vinayak MuralidharDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA; Kaiser Permanente Northwest, Portland, OR, USA.
Mark A PrestonDivision of Urologic Surgery, Brigham & Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA, USA.
Brendan ReardonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Jake R ConwayDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Catherine CurranDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Dory FreemanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Sybil ShaGeisel School of Medicine at Dartmouth, Hanover, NH, USA.
Guru SonpavdeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Michelle HirschDepartment of Pathology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA.
Adam S KibelDivision of Urologic Surgery, Brigham & Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA, USA.
Eliezer M Van AllenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: eliezerm_vanallen@dfci.harvard.edu.
Kent W MouwDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: kent_mouw@dfci.harvard.edu.
Dana-Farber Cancer Institute · USHarvard University · USBrigham and Women's Hospital · USDana-Farber Brigham Cancer Center · USDartmouth College · USKaiser Permanente · US

Funding

Training Program in Bioinformatics and Integrative GenomicsT32HG002295 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Peter J Park · 2001 to 2026
$15.8M
Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid TumorsR01CA227388 · NCI · DANA-FARBER CANCER INST · PI VAN ALLEN, ELIEZER M · 2018 to 2022
$2.0M
NCI NIH HHS R01 CA227388NHGRI NIH HHS T32 HG002295Wellcome Trust
6 · The paper itself

Abstract

backgroundMuscle-invasive bladder cancer (MIBC) is a rare but serious event following definitive radiation for prostate cancer. Radiation-associated MIBC (RA-MIBC) can be difficult to manage given the challenges of delivering definitive therapy to a previously irradiated pelvis. The genomic landscape of RA-MIBC and whether it is distinct from non-RA-MIBC are unknown.

objectiveTo define mutational features of RA-MIBC and compare the genomic landscape of RA-MIBC with that of non-RA-MIBC. DESIGN, SETTING, AND

participantsWe identified patients from our institution who received radiotherapy for prostate cancer and subsequently developed MIBC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We performed whole exome sequencing of bladder tumors from RA-MIBC patients. Tumor genetic alterations including mutations, copy number alterations, and mutational signatures were identified and were compared with genetic features of non-RA-MIBC. We used the Kaplan-Meier method to estimate recurrence-free (RFS) and overall (OS) survival. RESULTS AND LIMITATIONS: We identified 19 RA-MIBC patients with available tumor tissue (n = 22 tumors) and clinical data. The median age was 76 yr, and the median time from prostate cancer radiation to RA-MIBC was 12 yr. The median RFS was 14.5 mo and the median OS was 22.0 mo. Compared with a cohort of non-RA-MIBC analyzed in parallel, there was no difference in tumor mutational burden, but RA-MIBCs had a significantly increased number of short insertions and deletions (indels) consistent with previous radiation exposure. We identified mutation signatures characteristic of APOBEC-mediated mutagenesis, aging, and homologous recombination deficiency. The frequency of mutations in many known bladder cancer genes, including TP53, KDM6A, and RB1, as well as copy number alterations such as CDKN2A loss was similar in RA-MIBC and non-RA-MIBC.

conclusionsWe identified unique mutational properties that likely contribute to the distinct biological and clinical features of RA-MIBC. PATIENT SUMMARY: Bladder cancer is a rare but serious diagnosis following radiation for prostate cancer. We characterized genetic features of bladder tumors arising after prostate radiotherapy, and identify similarities with and differences from bladder tumors from patients without previous radiation.

Indexed as

Prostatic NeoplasmsUrinary Bladder NeoplasmsAgedFemaleGenomicsHumansMaleMusclesNeoplasm InvasivenessProstateBladder cancerDNA sequencingGenomicsMutational signaturesProstate cancerRadiationRadiation-associated cancerSecond malignancy

Identifiers

PMID34953602
PMCPMC9018481
OpenAlexW4200450230

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.